BD (Becton, Dickinson and Company), a leading global medical technology company, has announced that it has acquired Sirigen Group Limited, a developer of unique polymer dyes that are used in flow cytometry and can be applied to other technologies.

Sirigen’s polymer technology is based on Nobel Prize-winning research in conductive plastics and creates the potential for the development of novel dyes that are four to ten times brighter than conventional dyes – a breakthrough in the field.

"This new technology is a natural complement to our instrument platforms and reagent portfolio," said Alberto Mas, President, BD Biosciences. "We believe that the acquisition will enable us to develop a continuous cadence of novel, unique dyes and antibody specificity releases over the next two years, significantly expanding our life science research reagent portfolio with high-impact products."

"This acquisition is one more example of our pursuit of growth through innovation, in this case investing in a unique technology that enables us to differentiate our life science research reagent portfolio and add value for customers," said William A. Kozy, BD Executive Vice President.